Y-mAbs Therapeutics
NY - New YorkBiotechnology
Focus: Y-mAbs Therapeutics is a New York-based oncology-focused biotechnology company specializing in antibody therapies, with a commercial-stage asset (DANYELZA/naxitamab) and a deep pipeline of monoclonal antibodies and radioimmunoconjugates targeting pediatric and adult cancers.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
Open Jobs
0
About Y-mAbs Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Y-mAbs Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
29 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Peak
Only FDA-approved product; glycolipid GD2-directed monoclonal antibody representing primary revenue source and clinical validation of company's antibody platform.
Products & Portfolio (1)
Help build intelligence for Y-mAbs Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.